Do analysts rate ENVB or QNTM?

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 132.56%. Given Quantum Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Quantum Biopharma is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, ENVB or QNTM?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enveric Biosciences N/A N/A -$8.77M -$12.65 N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is ENVB or QNTM more profitable?

Enveric Biosciences' return on equity of -168.04% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -168.04% -145.95% Quantum Biopharma N/A -582.23% -184.20%

Do analysts prefer PLRZ or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, PLRZ or ENVB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Enveric Biosciences N/A N/A -$8.77M -$12.65 N/A

Is PLRZ or ENVB more profitable?

Polyrizon's return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Enveric Biosciences N/A -168.04% -145.95%

Do analysts rate ENVB or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ENVB or BGM?

Enveric Biosciences has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enveric Biosciences N/A N/A -$8.77M -$12.65 N/A BGM Group $37.92M 3.13 -$19.94M N/A N/A

Is ENVB or BGM more profitable?

BGM Group's return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -168.04% -145.95% BGM Group N/A N/A N/A

Do analysts prefer TXMD or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ENVB or AYTU?

Aytu BioPharma has a consensus target price of $14.50, indicating a potential upside of 600.48%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Aytu BioPharma is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Enveric Biosciences (ENVB) Competitors

$1.51 +0.03 (+2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$1.45 -0.06 (-4.24%)

As of 07:57 PM Eastern

Compare

ENVB vs. QNTM, PLRZ, BGM, TXMD, and AYTU

Should you buy Enveric Biosciences stock or one of its competitors? Enveric Biosciences's main competitors and comparable companies include Quantum Biopharma (QNTM), Polyrizon (PLRZ), BGM Group (BGM), TherapeuticsMD (TXMD), and Aytu BioPharma (AYTU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Enveric Biosciences compare to Quantum Biopharma?

Enveric Biosciences (NASDAQ:ENVB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Enveric Biosciences has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Quantum Biopharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Enveric Biosciences' return on equity of -168.04% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
Quantum Biopharma	N/A	-582.23%	-184.20%

In the previous week, Quantum Biopharma had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 1 mentions for Quantum Biopharma and 0 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.00 equaled Quantum Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Enveric Biosciences	Neutral
Quantum Biopharma	Neutral

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 132.56%. Given Quantum Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Quantum Biopharma is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Enveric Biosciences and Quantum Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

13.8% of Enveric Biosciences shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polyrizon has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

In the previous week, Polyrizon had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 3 mentions for Polyrizon and 0 mentions for Enveric Biosciences. Polyrizon's average media sentiment score of 0.73 beat Enveric Biosciences' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Positive
Enveric Biosciences	Neutral

Polyrizon's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Enveric Biosciences	N/A	-168.04%	-145.95%

Summary

Polyrizon beats Enveric Biosciences on 5 of the 8 factors compared between the two stocks.

How does Enveric Biosciences compare to BGM Group?

Enveric Biosciences (NASDAQ:ENVB) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Enveric Biosciences has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
BGM Group	$37.92M	3.13	-$19.94M	N/A	N/A

Enveric Biosciences has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

13.8% of Enveric Biosciences shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BGM Group had 6 more articles in the media than Enveric Biosciences. MarketBeat recorded 6 mentions for BGM Group and 0 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.00 beat BGM Group's score of -0.33 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Enveric Biosciences	Neutral
BGM Group	Neutral

BGM Group's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
BGM Group	N/A	N/A	N/A

Summary

BGM Group beats Enveric Biosciences on 6 of the 9 factors compared between the two stocks.

How does Enveric Biosciences compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has higher revenue and earnings than Enveric Biosciences. Enveric Biosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.85	-$570K	$0.02	102.50
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Enveric Biosciences	Neutral

TherapeuticsMD has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Enveric Biosciences has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Enveric Biosciences	N/A	-168.04%	-145.95%

Summary

TherapeuticsMD beats Enveric Biosciences on 7 of the 10 factors compared between the two stocks.

How does Enveric Biosciences compare to Aytu BioPharma?

Enveric Biosciences (NASDAQ:ENVB) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aytu BioPharma has a consensus target price of $14.50, indicating a potential upside of 600.48%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Aytu BioPharma is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Enveric Biosciences has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

In the previous week, Aytu BioPharma had 10 more articles in the media than Enveric Biosciences. MarketBeat recorded 10 mentions for Aytu BioPharma and 0 mentions for Enveric Biosciences. Aytu BioPharma's average media sentiment score of 0.77 beat Enveric Biosciences' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Enveric Biosciences	Neutral
Aytu BioPharma	Positive

Enveric Biosciences has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
Aytu BioPharma	$57.57M	0.39	-$14.25M	-$1.66	N/A

Enveric Biosciences has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Aytu BioPharma's return on equity of -56.54% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
Aytu BioPharma	-24.76%	-56.54%	-13.14%

Summary

Aytu BioPharma beats Enveric Biosciences on 11 of the 15 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENVB vs. The Competition

Export

Metric	Enveric Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.62M	$12.12B	$7.17B	$13.38B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	N/A	799.72	274.64	26.20
Price / Sales	N/A	755.20	608.57	91.20
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	0.22	10.68	11.26	6.40
Net Income	-$8.77M	$2.83B	$3.49B	$381.07M
7 Day Performance	2.72%	-2.20%	-1.68%	-0.66%
1 Month Performance	8.63%	-6.55%	-5.97%	-4.51%
1 Year Performance	-81.83%	-4.52%	8.11%	1.82%

Enveric Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENVB Enveric Biosciences	0.2149 of 5 stars	$1.51 +2.0%	N/A	-82.2%	$6.62M	N/A	N/A	6
QNTM Quantum Biopharma	1.8908 of 5 stars	$4.31 +16.4%	$8.00 +85.8%	-81.4%	$27.57M	N/A	N/A	7
PLRZ Polyrizon	1.2789 of 5 stars	$11.00 +3.2%	N/A	+46.9%	$26.40M	N/A	N/A	1	News Coverage Earnings Report
BGM BGM Group	0.9234 of 5 stars	$0.26 -1.1%	N/A	-96.7%	$24.79M	$37.92M	N/A	471
TXMD TherapeuticsMD	0.5331 of 5 stars	$2.14 -0.9%	N/A	+91.2%	$24.76M	$3.02M	107.00	420	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enveric Biosciences (ENVB) Competitors

ENVB vs. QNTM, PLRZ, BGM, TXMD, and AYTU

How does Enveric Biosciences compare to Quantum Biopharma?

Summary

How does Enveric Biosciences compare to Polyrizon?

Summary

How does Enveric Biosciences compare to BGM Group?

Summary

How does Enveric Biosciences compare to TherapeuticsMD?

Summary

How does Enveric Biosciences compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enveric Biosciences (ENVB) Competitors

ENVB vs. QNTM, PLRZ, BGM, TXMD, and AYTU

How does Enveric Biosciences compare to Quantum Biopharma?

Which has more volatility & risk, ENVB or QNTM?

Which has better valuation and earnings, ENVB or QNTM?

Is ENVB or QNTM more profitable?

Does the media prefer ENVB or QNTM?

Do insiders and institutionals have more ownership in ENVB or QNTM?

Do analysts rate ENVB or QNTM?

Summary

How does Enveric Biosciences compare to Polyrizon?

Do institutionals & insiders believe in PLRZ or ENVB?

Which has better earnings & valuation, PLRZ or ENVB?

Do analysts prefer PLRZ or ENVB?

Which has more risk & volatility, PLRZ or ENVB?

Does the media refer more to PLRZ or ENVB?

Is PLRZ or ENVB more profitable?

Summary

How does Enveric Biosciences compare to BGM Group?

Which has stronger valuation and earnings, ENVB or BGM?

Which has more risk and volatility, ENVB or BGM?

Do analysts rate ENVB or BGM?

Do insiders and institutionals believe in ENVB or BGM?

Does the media refer more to ENVB or BGM?

Is ENVB or BGM more profitable?

Summary

How does Enveric Biosciences compare to TherapeuticsMD?

Do analysts prefer TXMD or ENVB?

Which has stronger valuation & earnings, TXMD or ENVB?

Do institutionals and insiders have more ownership in TXMD or ENVB?

Does the media favor TXMD or ENVB?

Which has more risk and volatility, TXMD or ENVB?

Is TXMD or ENVB more profitable?

Summary

How does Enveric Biosciences compare to Aytu BioPharma?

Do institutionals & insiders have more ownership in ENVB or AYTU?

Do analysts prefer ENVB or AYTU?

Which has more volatility and risk, ENVB or AYTU?

Does the media favor ENVB or AYTU?

Which has higher earnings and valuation, ENVB or AYTU?

Is ENVB or AYTU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools